T43.1X2 Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm

Name of the Condition

• Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm
• Technical term: T43.1X2

Summary

This code describes intentional self-harm poisoning by monoamine-oxidase-inhibitor (MAOI) antidepressants. MAOIs are a class of medications used to treat depression and other mental health conditions. The code applies when clinical documentation specifies intentional overdose or self-inflicted exposure to these drugs, indicating suicidal intent.

Causes

Intentional self-harm poisoning results from deliberate ingestion of an MAOI in excess of prescribed or safe levels. This may involve taking multiple doses at once or combining the drug with other substances to cause harm. The act is driven by suicidal ideation or intent to self-injure.

Risk Factors

• Active suicidal ideation or prior suicide attempts.
• Untreated or poorly managed mental health conditions (e.g., depression, bipolar disorder).
• Access to medications without supervision or safety measures.
• Social isolation or lack of support systems.
• Concurrent substance use that impairs judgment.

Symptoms

Symptoms may include:

• Severe hypertension or hypertensive crisis (headache, chest pain, rapid heart rate).
• Altered mental status, confusion, or coma.
• Nausea, vomiting, or abdominal pain.
• Seizures or muscle rigidity.
• Flushing, sweating, or fever.
• Respiratory distress or failure.

Diagnosis

Diagnosis relies on clinical evaluation, including patient history (if available) and physical examination. Laboratory tests may confirm drug levels or metabolic disturbances. Documentation must specify intentional self-harm as the cause, with no ambiguity about intent. Differential diagnosis may rule out accidental poisoning or other medical conditions.

Treatment Options

Treatment focuses on stabilizing the patient and addressing immediate toxicity. This may include airway management, cardiovascular support, and administration of antidotes (e.g., cyproheptadine). Psychiatric evaluation and intervention are critical to address underlying mental health concerns. Long-term care may involve therapy, medication adjustment, or safety planning.

Prognosis and Follow-Up

Prognosis depends on the severity of poisoning, timeliness of treatment, and underlying mental health status. Early intervention improves outcomes. Follow-up includes ongoing psychiatric care, medication management, and monitoring for recurrence. Discharge planning should address safety measures and support systems.

Complications

Complications can include organ damage (e.g., liver or kidney failure), permanent neurological impairment, or death. Cardiovascular events (e.g., stroke, heart attack) may occur due to uncontrolled hypertension. Psychological complications, such as persistent suicidal ideation, require ongoing management.

Lifestyle & Prevention

Prevention involves secure storage of medications, limiting access for at-risk individuals, and education on safe dosing. Encouraging open communication about mental health and providing resources (e.g., crisis hotlines) can reduce risk. Regular follow-up with healthcare providers helps monitor medication use and mental health status.

When to Seek Professional Help

Seek immediate medical attention if self-harm is suspected or if symptoms of poisoning (e.g., severe headache, confusion, or respiratory distress) occur. Contact emergency services or a mental health professional if suicidal thoughts are present. Early intervention is critical to prevent severe harm.

Tips for Medical Coders

Document intent clearly in the medical record, as this code requires explicit specification of intentional self-harm. Ensure the encounter type (e.g., initial, subsequent) aligns with the code’s seventh character (if applicable). Verify that the drug is classified as an MAOI antidepressant and that no other codes better describe the scenario (e.g., accidental poisoning).